普瑞眼科(301239.SZ):擬使用1.15億元超募資金新建深圳普瑞眼科醫院(南山區)項目
格隆匯3月10日丨普瑞眼科(301239.SZ)公佈,公司於2023年3月10日召開第三屆董事會第十次會議和第三屆監事會第七次會議,分別審議通過了《關於使用部分超募資金新建深圳普瑞眼科醫院(南山區)項目的議案》,同意公司使用部分超募資金人民幣1.15億元新建深圳普瑞眼科醫院(南山區)項目。
項目建設內容:建築總面積為18,887.33平方米,總投資11,522.97萬元,其中裝修費7122.97元,醫療設備3000萬元,辦公設備200萬元,運輸設備100萬元,流動資金1000萬元,不可預計費100萬元。項目建設週期為2023年5月1日-2024年4月30日,建設期12個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.